EUVIMEDEUVIMED entdecken
Open Access

The landscape of chemotherapy modifications among women treated for stage I–IIIA breast cancer

Jenna Bhimani, Kelli O'Connell, Victoria S Blinder, Rachael Burganowski, Isaac J Ergas iD, Grace B Gallagher iD, Jennifer J Griggs, Narre Heon, Sankeerth Jinna iD, Tatjana Kolevska, Yuriy Kotsurovskyy, Candyce H Kroenke iD und 10 weitere

Cancer · 15.03.2026 · 132 (6)

DOI: 10.1002/cncr.70318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 11.03.2026. Verfasst von Jenna Bhimani und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Geoffrey Beene Cancer Research Center at the Memorial Sloan Kettering Cancer Center, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the delivery of cancer care, patients may experience modifications to their intended chemotherapy regimen for reasons such as toxicity, tolerability, and scheduling challenges. Understanding modifications from the intended chemotherapy in the real‐world setting of cancer care may affect treatment planning and inferences of real‐world treatment effectiveness.

Methods

By leveraging data from the Optimal Breast Cancer Chemotherapy Dosing Study, this research studied 12,558 women receiving chemotherapy for primary stage I–IIIA breast cancer at Kaiser Permanente Northern California (2006–2019) and Kaiser Permanente Washington (2004–2015). Modifications in chemotherapy administered from intended, both overall and by regimen, are described. Prevalence ratios (PRs) were calculated for associations between regimen attributes and treatment modifications via generalized linear models of the Poisson family with a log‐link function and robust standard errors.

Results

Intent to receive a guideline‐concordant regimen was associated with a lower likelihood of modifications from the intended chemotherapy (vs. non–guideline concordant) (PR, 0.74; 95% CI, 0.69–0.79), as was receiving a dose‐dense regimen (vs. non–dose dense) (PR, 0.84; 95% CI, 0.78–0.91). Those receiving any neoadjuvant chemotherapy (vs. adjuvant only) were more likely to have modifications from the intended chemotherapy (PR, 1.29; 95% CI, 1.19–1.41). Increasing numbers of cycles and drugs administered were associated with a higher likelihood of modifications ( p trend < .001).

Conclusions

Breast cancer chemotherapy regimens used in the real‐world setting were examined. Chemotherapy modifications varied markedly by regimen and by characteristics of the regimen administered. Given that more than one in three women in this cohort did not receive chemotherapy as intended, these novel findings may be informative in treatment planning and for future research assessing real‐world treatment effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleNeoplasm StagingMiddle AgedAgedAdultChemotherapy, AdjuvantCalifornia

Stichwörter der Autor:innen

breast cancerbreast neoplasmchemotherapychemotherapy modificationelectronic health recordstreatment

Autor:innen und Institutionen

  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, USA.
  • Division of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
  • Division of Hematology/Oncology, Department of Medicine and Department of Health Management and Policy, University of Michigan, Ann Arbor, Michigan, USA.
  • Department of Oncology, Kaiser Permanente Medical Center, Vallejo, California, USA.

ORCID-Profile: Isaac J Ergas, Grace B Gallagher, Sankeerth Jinna, Candyce H Kroenke, Erin J Aiello Bowles, Elizabeth D Kantor

Förderung

  • NCI NIH HHS
  • Geoffrey Beene Cancer Research Center at the Memorial Sloan Kettering Cancer Center
  • National Cancer Institute

Zitieren

APA

Bhimani, J., O'Connell, K., Blinder, V. S., Burganowski, R., Ergas, I. J., Gallagher, G. B., Griggs, J. J., Heon, N., Jinna, S., Kolevska, T., Kotsurovskyy, Y., Kroenke, C. H., Laurent, C. A., Liu, R., Nakata, K. G., Persaud, S., Roh, J. M., Valice, E., Bandera, E. V., …, & Kantor, E. D. (2026). The landscape of chemotherapy modifications among women treated for stage I–IIIA breast cancer. Cancer, 132(6). https://doi.org/10.1002/cncr.70318

Vancouver

Bhimani J, O'Connell K, Blinder VS, Burganowski R, Ergas IJ, Gallagher GB, et al. The landscape of chemotherapy modifications among women treated for stage I–IIIA breast cancer. Cancer. 2026;132(6). doi:10.1002/cncr.70318

BibTeX
@article{Bhimani2026,
  author = {Bhimani, Jenna and O'Connell, Kelli and Blinder, Victoria S and Burganowski, Rachael and Ergas, Isaac J and Gallagher, Grace B and Griggs, Jennifer J and Heon, Narre and Jinna, Sankeerth and Kolevska, Tatjana and Kotsurovskyy, Yuriy and Kroenke, Candyce H and Laurent, Cecile A and Liu, Raymond and Nakata, Kanichi G and Persaud, Sonia and Roh, Janise M and Valice, Emily and Bandera, Elisa V and Bowles, Erin J Aiello and Kushi, Lawrence H and Kantor, Elizabeth D},
  title = {The landscape of chemotherapy modifications among women treated for stage I–IIIA breast cancer},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {6},
  doi = {10.1002/cncr.70318}
}
Kostenlos starten →